The company said it completed its acquisition of ImmunoGen on February 12, 2024 and acquired all outstanding ImmunoGen common stock for $31.26 per share.

8-KRegulation FD DisclosureFiled Feb 12, 2024Period of report Feb 12, 2024Summary published (UTC) Oct 31, 2026

Key points

AI summary

The company said it completed its acquisition of ImmunoGen on February 12, 2024 and acquired all outstanding ImmunoGen common stock for $31.26 per share.
AbbVie reaffirmed its full-year 2024 adjusted diluted EPS guidance range of $11.05 to $11.25. The company said the guidance now includes a dilutive impact of $0.42 per share related to the ImmunoGen acquisition and the pending Cerevel Therapeutics acquisition.
The company said it updated its adjusted diluted EPS guidance for Q1 2024 to $2.26 to $2.30 from the previous range of $2.30 to $2.34. It said the range includes a dilutive impact of $0.04 per share related to the ImmunoGen acquisition.
The company said that with the ImmunoGen acquisition it added ELAHERE to its portfolio and expects the acquisition to be accretive to diluted EPS beginning in 2027.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

ImmunoGen Acquisition Completed at $31.26 per Share

The company said it completed its acquisition of ImmunoGen on February 12, 2024 and acquired all outstanding ImmunoGen common stock for $31.26 per share.

Source · Based on the filing body and exhibits

Full-Year Adjusted EPS Guidance Reaffirmed, Including $0.42 Dilutive Impact

AbbVie reaffirmed its full-year 2024 adjusted diluted EPS guidance range of $11.05 to $11.25. The company said the guidance now includes a dilutive impact of $0.42 per share related to the ImmunoGen acquisition and the pending Cerevel Therapeutics acquisition.

Source · Based on the filing body and exhibits

Adjusted Diluted EPS Guidance Updated for Q1 2024

The company said it updated its adjusted diluted EPS guidance for Q1 2024 to $2.26 to $2.30 from the previous range of $2.30 to $2.34. It said the range includes a dilutive impact of $0.04 per share related to the ImmunoGen acquisition.

Source · Based on the filing body and exhibits

ELAHERE Added to Portfolio; Timing of Diluted EPS Accretion

The company said that with the ImmunoGen acquisition it added ELAHERE to its portfolio and expects the acquisition to be accretive to diluted EPS beginning in 2027.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.